Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction

Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies’ production. Recently, the US Food and Drug Administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Hamdy MA, Abohamad, Samar, Elfishawi, Mohanad, Hegazy, Mohamed Tharwat, Vijaykumar, Kadambari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254654/
https://www.ncbi.nlm.nih.gov/pubmed/30538431
http://dx.doi.org/10.2147/PPA.S147163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254654/
https://www.ncbi.nlm.nih.gov/pubmed/30538431
http://dx.doi.org/10.2147/PPA.S147163

Ejemplares similares